Anti-Estrogen Receptor beta 5 Antibody [5/25] (A278864)

Anti-Estrogen Receptor beta 5 Antibody [5/25]

Mouse monoclonal [5/25] antibody to Estrogen Receptor beta 5.

This antibody recognises human estrogen receptor beta 5 (ERB5), a splice variant of the nuclear receptor hormone ERbeta (ESR2), one of at least five isoforms. Although only the ERB1 variant appears fully functional, the remaining isoforms have been shown to form heterodimers with ERB1, thereby enhancing transcription. ERB5 is expressed in normal colorectal tissue, and is present in primary colorectal carcinomas. The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient’s prognosis and the effectiveness of hormonal therapy transcription (Shaaban et al. 2008, Collins et al. 2009).

WB, IHC-P

Human

Tuberculin conjugated synthetic peptide LLSHVRHARYAP derived from the C-terminus of human ERB5.

Mouse

Monoclonal

5/25

IgG1

1 mg/ml

Liquid

Supplied in Phosphate Buffered Saline with 0.1% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Mouse anti human estrogen receptor beta 5, clone 5/25 recognizes human estrogen receptor beta 5 (ERB5), a splice variant of the nuclear receptor hormone ERbeta (ESR2), one of at least five isoforms (Moore et al. 1998). Although only the ERB1 variant appears fully functional, the remaining isoforms have been shown to form heterodimers with ERB1, thereby enhancing transcription (Shaaban et al. 2008).ERB5 is expressed in normal colorectal tissue, and is present in primary colorectal carcinomas (Wong et al. 2005).The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient’s prognosis and the effectiveness of hormonal therapy transcription (Shaaban et al. 2008, Collins et al. 2009).